Daily Endocrinology Research Analysis
Top endocrinology advances today include: new international guidelines for pediatric X-linked hypophosphatemia that synthesize GRADE-based evidence and standardize diagnosis, treatment (including burosumab), and monitoring; a mechanistic neuroendocrine study identifying Fam172a in hypothalamic oxytocin neurons as a key regulator of obesity-induced anxiety; and a meta-analysis of randomized trials showing tirzepatide improves albuminuria without harming eGFR in people with type 2 diabetes or obes
Summary
Top endocrinology advances today include: new international guidelines for pediatric X-linked hypophosphatemia that synthesize GRADE-based evidence and standardize diagnosis, treatment (including burosumab), and monitoring; a mechanistic neuroendocrine study identifying Fam172a in hypothalamic oxytocin neurons as a key regulator of obesity-induced anxiety; and a meta-analysis of randomized trials showing tirzepatide improves albuminuria without harming eGFR in people with type 2 diabetes or obesity.
Research Themes
- Evidence-based pediatric bone endocrinology (XLH guidelines)
- Neuroendocrine mechanisms linking obesity and anxiety (oxytocin neurons, Fam172a)
- Renal outcomes of incretin-based therapies (tirzepatide) in diabetes/obesity
Selected Articles
1. Fam172a Mediates the Stimulation of Hypothalamic Oxytocin Neurons to Suppress Obesity-Induced Anxiety.
In mice, activation of paraventricular hypothalamic oxytocin neurons reduced obesity-induced anxiety-like behavior, while inhibition worsened it. The anxiety susceptibility gene Fam172a is enriched in these neurons, downregulated by high-fat diet/stress, and modulates intranuclear Argonaute 2 and mRNA degradation to control oxytocin secretion; gain- and loss-of-function experiments respectively ameliorated or exacerbated anxiety-like behavior.
Impact: This uncovers a previously unrecognized neuroendocrine mechanism linking obesity to anxiety via Fam172a-driven regulation of oxytocin neurons, opening a targetable pathway at the interface of metabolism and mental health.
Clinical Implications: While preclinical, the work nominates oxytocin signaling and Fam172a as candidate targets for obesity-associated anxiety, motivating biomarker development and human translational studies in neuroendocrine circuits.
Key Findings
- Activation of PVN oxytocin neurons ameliorated obesity-induced anxiety-like behavior; inhibition worsened it.
- Fam172a is highly expressed in PVN oxytocin neurons but is downregulated by high-fat diet and acute stress.
- Fam172a modulates intranuclear transport of Argonaute 2, influencing mRNA degradation and oxytocin secretion.
- Overexpression of Fam172a improved, while disruption exacerbated, obesity-anxiety-like behavior in mice.
Methodological Strengths
- In vivo gain- and loss-of-function manipulations of PVN oxytocin neurons with behavioral readouts
- Mechanistic linkage via Argonaute 2–mediated mRNA regulation corroborated across diet and stress models
Limitations
- Findings are limited to murine models; human relevance and peripheral biomarkers remain untested
- Behavioral phenotyping and circuit specificity may not capture the full complexity of human anxiety disorders
Future Directions: Validate Fam172a and oxytocin pathway markers in humans with obesity-associated anxiety; develop selective modulators or gene therapy approaches and test causality with neuromodulation.
Anxiety disorder is the most common mental disorder worldwide. Although human studies have demonstrated a positive association between obesity and anxiety disorder, the exact mechanism linking these conditions is unclear. Interestingly, oxytocin (Oxt) neurons, predominantly expressed in the hypothalamic paraventricular nucleus (PVN), play a crucial role in both obesity and anxiety. In this study, obesity can induce anxiety-like behavior in mice, which can be ameliorated by the activation of PVN Oxt neurons. Conversely, inhibiting PVN Oxt neurons accelerate the progression of anxiety. Moreover, the family with sequence similarity 172, member A (Fam172a), an anxiety susceptibility gene, is highly expressed in the hypothalamic PVN Oxt neuron but reduce in the PVN Oxt neuron of mice in the high-fat diet and acute restraint stress conditions. Significantly, overexpression of Fam172a in PVN Oxt neurons improve obesity-anxiety-like behavior in mice. In contrast, disruption of Fam172a in PVN Oxt neurons exacerbate obesity-anxiety-like behavior. Furthermore, this study demonstrates that Fam172a is involved in mRNA degradation in Oxt neurons by regulating the intranuclear transport of Argonaute 2, thereby influencing Oxt secretion and ultimately impacting obesity-anxiety-like behavior. These findings suggest that Fam172a serves as a key target of PVN Oxt neurons in the regulation of obesity-induced anxiety.
2. X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline.
An international panel produced GRADE-based pediatric XLH guidelines integrating two systematic reviews and expert survey to standardize diagnosis, treatment (including burosumab vs conventional therapy), and monitoring. The guideline also highlights dental complications and proposes mitigation strategies.
Impact: These guidelines will directly shape multidisciplinary pediatric endocrine care for XLH, aligning practice with current evidence and clarifying the role of burosumab and genetic testing.
Clinical Implications: Adopt structured diagnostic pathways including biochemical assessment and targeted genetic testing; consider burosumab as a key therapeutic option with defined monitoring, and implement dental preventive strategies.
Key Findings
- Provides a structured approach to establish pediatric XLH diagnosis, including the role of genetic testing.
- GRADEd recommendations contrast burosumab with conventional therapy and synthesize benefits/harms.
- Monitoring recommendations are graded weak with very low certainty, reflecting current evidence gaps.
- Addresses dental complications in XLH and proposes mitigation strategies.
Methodological Strengths
- Use of GRADE methodology with two underpinning systematic reviews
- Large, international, multidisciplinary panel with patient partner input
Limitations
- Monitoring recommendations rely on expert survey and are graded with very low certainty
- Heterogeneity of underlying evidence and pediatric rarity limit generalizability and strength of some recommendations
Future Directions: Prospective, multicenter studies to strengthen monitoring evidence, long-term safety/effectiveness of burosumab, and standardized dental outcome reporting.
CONTEXT: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children. Over the past 5 years, important advances have occurred in our understanding of the presentation, complications, and treatment of XLH. METHODS: A group of 50 international experts in XLH from Canada, the United States, Europe, Asia, and South America, along with methodology experts and a patient partner, held 18 teleconference meetings in 2023-2024. These meetings addressed key issues regarding diagnosing, evaluating, managing, and monitoring XLH in children. Two systematic reviews were conducted to examine the impact of burosumab compared to conventional therapy (phosphate salts and active vitamin D) or no therapy, and to assess the impact of conventional therapy vs no therapy on patient-important outcomes. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Additionally, narrative reviews were completed on XLH diagnosis and the role of genetic testing, and an expert clinical practice survey informed the monitoring recommendations. OUTCOMES: An approach to establishing the diagnosis of XLH is presented. GRADEd recommendations were developed on treatment strategies for XLH in children. Monitoring recommendations, GRADEd as weak with very low certainty, were based on clinical practice survey of the IWG experts. The guidelines also addressed dental complications and proposed potential strategies to mitigate them. CONCLUSION: These clinical practice guidelines provide an update of the current evidence on the diagnosis and management of XLH and provide a comprehensive guidance for multidisciplinary healthcare professionals involved in the care of children with XLH.
3. Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis.
Across 15 RCTs, tirzepatide reduced UACR without harming eGFR in people with T2D and in those with obesity without diabetes, indicating potential renal benefit and reassuring safety in the short term.
Impact: Given tirzepatide’s rapid uptake in diabetes/obesity care, synthesized RCT evidence on renal outcomes informs drug choice and risk–benefit discussions pending dedicated renal outcome trials.
Clinical Implications: Clinicians can anticipate albuminuria improvements with tirzepatide without short-term eGFR penalty; monitoring UACR may aid risk stratification, while awaiting longer-term renal outcome data.
Key Findings
- Meta-analysis of RCTs indicates tirzepatide reduces UACR compared with control conditions.
- No detrimental effect on eGFR was observed in short-term RCTs across T2D and obesity populations.
- Overall renal safety profile was reassuring; longer-term, hard renal outcomes remain to be established.
Methodological Strengths
- Synthesis of randomized controlled trials with low risk of bias
- Assessment across indications (T2D and obesity) with co-primary renal outcomes (UACR, eGFR)
Limitations
- Short follow-up horizons preclude conclusions on hard renal endpoints (e.g., sustained eGFR decline, ESKD)
- Heterogeneity of comparators and trial populations; individual patient data were not analyzed
Future Directions: Conduct long-duration, dedicated renal outcome trials of tirzepatide and IPD meta-analyses to define effects on eGFR slope, CKD progression, and albuminuria regression.
BACKGROUND: Type 2 diabetes (T2D), as well as obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The renal impacts of glucose-lowering and weight-lowering drugs and their potential benefits in preventing CKD often guide clinicians in choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available on the renal effects and safety profile of tirzepatide. AIM: To explore the renal benefits and safety of tirzepatide METHODS: RCTs involving patients receiving tirzepatide for any indication in the intervention arm and placebo or active comparator in the control arm were searched through multiple electronic databases. The co-primary outcomes were percent change from baseline (CFB) in urine albumin-to-creatinine ratio (UACR) and absolute CFB in estimated glomerular filtration rate (eGFR; in mL/min/1.73 m RESULTS: Fifteen RCTs ( CONCLUSION: Short-term data from RCTs with low RoB suggests that tirzepatide positively impacts UACR without detrimental effects on eGFR in subjects with T2D and obesity without T2D, with a reassuring renal safety profile. Larger RCTs are warranted to prove the longer-term renal benefits of tirzepatide, which might also prevent eGFR decline and worsening of CKD.